Early detection program for subtle memory and thinking changes in older adults
Official title: German: COGSCREEN II: Früherkennung Kognitiver Störungen Durch Screeningverfahren Von Haus- Und Fachärzten Bei Senioren in Deutschland English: COGSCREEN II: Early Detection of Cognitive Impairment Through Screening Procedures by General Practitioners and Specialists in Older Adults in Germany (DAC AccDx Munich Site)
Run by Ludwig-Maximilians - University of Munich · NCT07466394 · Data updated 2026-11-12
This project will test a targeted cognitive screening program to find early memory and thinking problems in people aged 60 and older who notice changes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 60 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Ludwig-Maximilians - University of Munich Academic / other |
| Locations | 1 site (München) |
| Status | Recruiting |
| Started | June 1, 2025 |
| Main results expected | July 1, 2027 |
| Study ends | July 1, 2027 |
| Registry record updated | March 12, 2026 |
| Trial ID | NCT07466394 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 60 or older who can give informed consent and who report subjective cognitive decline or have mild cognitive impairment without a prior dementia diagnosis.
✕Probably not a fit
Patients who already have a dementia diagnosis, who cannot hear or see well enough for testing, or who are under 60 are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional program offers targeted cognitive screening to older adults with subjective cognitive decline or mild cognitive impairment to detect early Alzheimer's-related changes. Participants at LMU Klinikum undergo standardized cognitive tests and may be offered biomarker evaluation such as cerebrospinal fluid testing when indicated to identify an AD-typical profile. The aim is to implement a standardized pathway for identifying minimal cognitive decline in routine care so that at-risk individuals can be referred for monitoring, preventive measures, or emerging disease-modifying treatments. Enrollment includes people aged 60 or older who can consent and excludes those with a prior dementia diagnosis or sensory impairments that prevent testing.
Why it matters
Potential benefit: If successful, this approach could help people with early memory changes get diagnosed sooner, access appropriate monitoring or treatments earlier, and plan for the future.
How similar studies have gone: Research using cognitive screening plus biomarkers has shown promise for identifying prodromal Alzheimer's in specialized settings, but routine, targeted early-detection systems are not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female ≥ 60 years of age at the time of consent * Able to understand and voluntarily sign an informed consent according to the judgment of the practice team Exclusion Criteria: * Subjects who are unable to hear or see well enough to complete the assessments * Prior diagnosis of dementia (with or without evidence of pathology) as documented in the medical record and/or diagnosed by a physician
Where it's running
-
Klinik für Psychiatrie und Psychotherapie am LMU Klinikum
München, Germany Recruiting
Study contacts
- Study coordinator: Prof. Dr. Robert Perneczky
- Email: robert.perneczky@med.uni-muenchen.de
- Phone: +89440055772
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease in Real World Practice
This study will look at real-world safety and effectiveness of disease-modifying therapy (DMT) in adults with MCI or Alzheimer's dementia by comparing those who receive DMT in routine care to those who do not.
-
Automated language analysis to help diagnose neurodegenerative diseases
A multilingual AI-powered language test is being tried to see if speech and language patterns can help differentiate Alzheimer’s, frontotemporal dementia, Lewy body dementia, and Parkinson’s from healthy aging.
-
LIFU to Help Sleep and Amyloid Reduction in Older Adults with Cognitive Impairment
A wearable ultrasound device (ATTN201) is being tested to see if it’s safe and easy to use for people 65 and older with mild cognitive impairment and amyloid buildup.
-
Urolithin A for early Alzheimer’s disease: a test with a nutritional supplement
This trial tests whether taking urolithin A in addition to standard care helps people with early Alzheimer’s or mild cognitive impairment show better biomarkers and cognition.
-
Longitudinal profiling of plasma-derived glial extracellular vesicles in Alzheimer's disease
This study tests whether plasma glial extracellular vesicles and neuroinflammation biomarkers change over time across the Alzheimer’s disease spectrum and whether these signals relate to amyloid, tau, and neurodegeneration, with an additional step of exposing healthy iPSC-derived neurons to vesicles to see potential ne
-
Biomarker Repository for Age-Related and Inherited Neurodegenerative Diseases
This study collects blood and genetic samples from people with neurodegenerative diseases and their families to build a shared resource for studying disease risk and biology.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.